Cardiovascular Diagnostics files for monitoring tests:
This article was originally published in Clinica
Cardiovascular Diagnostics is seeking US clearance for two tests to monitor the effects of anti-clotting drugs. The Ecarin clotting time test is designed to monitor the effects of the thrombin inhibitor PEG-Hirudin, made by German pharmaceutical company Knoll. The low range heparin management test measures heparin levels in the ranges needed during cardiac catheterisation. Both tests are based on the company's Thrombolytic Assessment System, a dry chemistry technology platform from which it has developed a range of therapeutic diagnostics for angina, heart attack, stroke and deep vein thrombosis and pulmonary and arterial emboli.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.